<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03820778</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00010431</org_study_id>
    <nct_id>NCT03820778</nct_id>
  </id_info>
  <brief_title>Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1</brief_title>
  <official_title>Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 and High Plexiform Neurofibroma Tumor Burden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's National Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to determine if Whole Body MRI (WBMRI) can be used to identify
      Atypical Neurofibromas (ANF) in Neurofibromatosis Type 1 (NF1) patients with high tumor
      burden. Each enrolled participant will have two (2) WBMRIs without sedation during the study
      period. Eligible participants must be Male or Female between the ages of 8-30 with diagnosed
      NF1; with one or more PN greater than 3cm in diameter and willing to comply with study
      procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to determine the feasibility of using Whole Body MRI (WBMRI) to detect
      Atypical Plexiform Neurofibromas (ANF) among Neurofibromatosis Type 1 (NF1) patients who are
      at highest risk for developing these tumors. In order to do this, the investigators will
      prospectively obtain WBMRI scans on patients with high plexiform tumor burden (which
      investigators will define as &gt;=1 plexiform neurofibroma (PN) that is &gt;3cm in diameter on MRI)
      at the same time as their regularly scheduled MRI to allow for radiographic comparison of the
      identified PNs. In this study, the investigators will plan to establish a method that
      effectively characterizes PNs in terms of their volume, radiographic appearance on WBMRI and
      association with clinical characteristics.

      As an exploratory aim, the investigators plan to collect blood samples from each patient at
      the same time as the MRI to determine the feasibility of isolating cfDNA (circulating free
      DNA) from plasma of patients with high plexiform tumor burden.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Anticipated">July 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 12, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine if WBMRI can be used to identify ANF in NF1 patients with high tumor burden.</measure>
    <time_frame>2-3 years</time_frame>
    <description>We will review results of the WBMRI compared to regional MRIs (done with contrast) to determine if the WBMRI can accurately detect Atypical Neurofibromas.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine if clinical signs and symptoms correlate with tumor burden and/or the presence of ANF on WBMRI</measure>
    <time_frame>2-3 years</time_frame>
    <description>Using patient data collected during their routine clinic evaluation, we will determine if clinical signs and symptoms correlate with tumor burden and/or the presence of ANF on WBMRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine if the cfDNA levels correlate with presence of ANF.</measure>
    <time_frame>3-4 years</time_frame>
    <description>We will measure cfDNA levels in each participant, and determine if these levels correlate with tumor burden and/or the presence of ANFs.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Neurofibromatosis 1</condition>
  <condition>Neurofibroma</condition>
  <condition>Atypical Neurofibroma</condition>
  <condition>Atypical Neurofibromatosis</condition>
  <condition>Plexiform Neurofibroma</condition>
  <condition>Von Recklinghausen Disease</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole Body MRI along with standard of care regional MRI and blood draw at enrollment followed by Whole Body MRI along with standard of care regional MRI and blood draw after 4-6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Whole Body MRI</intervention_name>
    <description>WBMRI with axial and coronal STIR (short inversion time inversion recovery) images + DWI (diffuse weighted imaging) will be performed and compared to regional MRI to assess value of this diagnostic test for the identification of suspicious looking lesions (i.e. diffuse nodular lesions or atypical plexiform neurofibroma)</description>
    <arm_group_label>Study Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females between 8-30 years of age

          2. Confirmed diagnosis of NF1

          3. Stated willingness to comply with all study procedures and availability for the
             duration of the study

          4. Prior MRI documentation confirming &gt;=1 PN that is &gt;3cm in diameter

        Exclusion Criteria:

          1. Unable to undergo MRI without sedation

          2. Presence of metal or other devices that are contraindicated for MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Bornhorst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Health System</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, Friedman JM, Mautner VF. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012 Oct 4;7:75. doi: 10.1186/1750-1172-7-75.</citation>
    <PMID>23035791</PMID>
  </reference>
  <reference>
    <citation>Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. Sarcoma. 2017;2017:7429697. doi: 10.1155/2017/7429697. Epub 2017 May 16. Review.</citation>
    <PMID>28592921</PMID>
  </reference>
  <reference>
    <citation>Higham CS, Dombi E, Rogiers A, Bhaumik S, Pans S, Connor SEJ, Miettinen M, Sciot R, Tirabosco R, Brems H, Baldwin A, Legius E, Widemann BC, Ferner RE. The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors. Neuro Oncol. 2018 May 18;20(6):818-825. doi: 10.1093/neuonc/noy013.</citation>
    <PMID>29409029</PMID>
  </reference>
  <reference>
    <citation>Beert E, Brems H, Daniëls B, De Wever I, Van Calenbergh F, Schoenaers J, Debiec-Rychter M, Gevaert O, De Raedt T, Van Den Bruel A, de Ravel T, Cichowski K, Kluwe L, Mautner V, Sciot R, Legius E. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32. doi: 10.1002/gcc.20921. Epub 2011 Aug 24.</citation>
    <PMID>21987445</PMID>
  </reference>
  <reference>
    <citation>Mautner VF, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, Widemann BC, Friedman JM. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol. 2008 Aug;10(4):593-8. doi: 10.1215/15228517-2008-011. Epub 2008 Jun 17.</citation>
    <PMID>18559970</PMID>
  </reference>
  <reference>
    <citation>Domínguez-Vigil IG, Moreno-Martínez AK, Wang JY, Roehrl MHA, Barrera-Saldaña HA. The dawn of the liquid biopsy in the fight against cancer. Oncotarget. 2017 Dec 8;9(2):2912-2922. doi: 10.18632/oncotarget.23131. eCollection 2018 Jan 5. Review.</citation>
    <PMID>29416824</PMID>
  </reference>
  <reference>
    <citation>Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012;7(4):e35711. doi: 10.1371/journal.pone.0035711. Epub 2012 Apr 27.</citation>
    <PMID>22558206</PMID>
  </reference>
  <reference>
    <citation>Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO; Whole Body MRI Committee for the REiNS International Collaboration; REiNS International Collaboration Members 2016. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016 Aug 16;87(7 Suppl 1):S31-9. doi: 10.1212/WNL.0000000000002929.</citation>
    <PMID>27527647</PMID>
  </reference>
  <reference>
    <citation>Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar;250(3):665-73. doi: 10.1148/radiol.2503080700.</citation>
    <PMID>19244040</PMID>
  </reference>
  <reference>
    <citation>Wasa J, Nishida Y, Tsukushi S, Shido Y, Sugiura H, Nakashima H, Ishiguro N. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol. 2010 Jun;194(6):1568-74. doi: 10.2214/AJR.09.2724.</citation>
    <PMID>20489098</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 4, 2019</study_first_submitted>
  <study_first_submitted_qc>January 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's National Research Institute</investigator_affiliation>
    <investigator_full_name>Miriam Bornhorst</investigator_full_name>
    <investigator_title>Assistant Professor Division of Oncology and Center for Genetics Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Neurofibroma, Plexiform</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

